Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo

Chen-Hung Lee,1 Ming-Jer Hsieh,1 Shang-Hung Chang,1 Kuo-Chun Hung,1 Chao-Jan Wang,2 Ming-Yi Hsu,2 Jyuhn-Huarng Juang,3 I-Chang Hsieh,1 Ming-Shien Wen,1 Shih-Jung Liu4,5 1Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou, Chang Gung University College of Med...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lee CH, Hsieh MJ, Chang SH, Hung KC, Wang CJ, Hsu MY, Juang JH, Hsieh IC, Wen MS, Liu SJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	re-endothelialization neointimal hyperplasia vildagliptin biodegradable drug-eluting nanofibers; Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/2275f98c1f4f435997c75585a3008f42
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2275f98c1f4f435997c75585a3008f42
record_format	dspace
spelling	oai:doaj.org-article:2275f98c1f4f435997c75585a3008f422021-12-02T05:04:44ZNanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo1178-2013https://doaj.org/article/2275f98c1f4f435997c75585a3008f422019-09-01T00:00:00Zhttps://www.dovepress.com/nanofibrous-vildagliptin-eluting-stents-enhance-re-endothelialization--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Chen-Hung Lee,1 Ming-Jer Hsieh,1 Shang-Hung Chang,1 Kuo-Chun Hung,1 Chao-Jan Wang,2 Ming-Yi Hsu,2 Jyuhn-Huarng Juang,3 I-Chang Hsieh,1 Ming-Shien Wen,1 Shih-Jung Liu4,5 1Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou, Chang Gung University College of Medicine, Linkou, Taiwan; 2Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Linkou, Tao-Yuan, Taiwan; 3Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung University and Chang Gung Memorial Hospital, Tao-Yuan, Taiwan; 4Department of Mechanical Engineering, Chang Gung University, Tao-Yuan, Taiwan; 5Department of Orthopedic Surgery, Chang Gung Memorial Hospital-Linkou, Tao-Yuan 33305, TaiwanCorrespondence: Shih-Jung LiuBiomaterials Lab, Department of Mechanical Engineering, Chang Gung University, 259, Wen-Hwa 1st Road, Kwei-Shan, Tao-Yuan 333, TaiwanTel +886 3 211 8166Fax +886 3 211 8558Email profsjliu5347@gmail.comBackground: The high lifetime risk of vascular disease is one of the important issues that plague patients with diabetes mellitus. Systemic oral vildagliptin administration favors endothelial recovery and inhibits smooth muscle cell (SMC) proliferation. However, the localized release of vildagliptin in the diabetic vessel damage has seldom been investigated.Research design and methods: In this work, nanofiber-eluting stents that loaded with vildagliptin, a dipeptidyl peptidase-4 enzyme (DPP-4) inhibitor, was fabricated to treat diabetic vascular disease. To prepare nanofibers, the poly (D,L)-lactide-co-glycolide (PLGA) and vildagliptin were mixed using hexafluoroisopropanol and electrospinning process. In vitro and in vivo release rates of the vildagliptin were characterized using high-performance liquid chromatography.Results: Effective vildagliptin concentrations were delivered for more than 28 days from the nanofibrous membranes coating on the surface of the stents in vitro and in vivo. The vildagliptin-eluting PLGA membranes greatly accelerated the recovery of diabetic endothelia and reduced SMC hyperplasia. The type I collagen content of the diabetic vascular intimal area that was treated by vildagliptin-eluting stents was lower than that of the non-vildagliptin-eluting group.Conclusion: The experimental results revealed that stenting with vildagliptin-eluting PLGA membranes could potentially promote healing for diabetic arterial diseases.Keywords: re-endothelialization, neointimal hyperplasia, vildagliptin, biodegradable drug-eluting nanofibersLee CHHsieh MJChang SHHung KCWang CJHsu MYJuang JHHsieh ICWen MSLiu SJDove Medical Pressarticlere-endothelializationneointimal hyperplasiavildagliptinbiodegradable drug-eluting nanofibers;Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 7503-7513 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	re-endothelialization neointimal hyperplasia vildagliptin biodegradable drug-eluting nanofibers; Medicine (General) R5-920
spellingShingle	re-endothelialization neointimal hyperplasia vildagliptin biodegradable drug-eluting nanofibers; Medicine (General) R5-920 Lee CH Hsieh MJ Chang SH Hung KC Wang CJ Hsu MY Juang JH Hsieh IC Wen MS Liu SJ Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo
description	Chen-Hung Lee,1 Ming-Jer Hsieh,1 Shang-Hung Chang,1 Kuo-Chun Hung,1 Chao-Jan Wang,2 Ming-Yi Hsu,2 Jyuhn-Huarng Juang,3 I-Chang Hsieh,1 Ming-Shien Wen,1 Shih-Jung Liu4,5 1Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou, Chang Gung University College of Medicine, Linkou, Taiwan; 2Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Linkou, Tao-Yuan, Taiwan; 3Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung University and Chang Gung Memorial Hospital, Tao-Yuan, Taiwan; 4Department of Mechanical Engineering, Chang Gung University, Tao-Yuan, Taiwan; 5Department of Orthopedic Surgery, Chang Gung Memorial Hospital-Linkou, Tao-Yuan 33305, TaiwanCorrespondence: Shih-Jung LiuBiomaterials Lab, Department of Mechanical Engineering, Chang Gung University, 259, Wen-Hwa 1st Road, Kwei-Shan, Tao-Yuan 333, TaiwanTel +886 3 211 8166Fax +886 3 211 8558Email profsjliu5347@gmail.comBackground: The high lifetime risk of vascular disease is one of the important issues that plague patients with diabetes mellitus. Systemic oral vildagliptin administration favors endothelial recovery and inhibits smooth muscle cell (SMC) proliferation. However, the localized release of vildagliptin in the diabetic vessel damage has seldom been investigated.Research design and methods: In this work, nanofiber-eluting stents that loaded with vildagliptin, a dipeptidyl peptidase-4 enzyme (DPP-4) inhibitor, was fabricated to treat diabetic vascular disease. To prepare nanofibers, the poly (D,L)-lactide-co-glycolide (PLGA) and vildagliptin were mixed using hexafluoroisopropanol and electrospinning process. In vitro and in vivo release rates of the vildagliptin were characterized using high-performance liquid chromatography.Results: Effective vildagliptin concentrations were delivered for more than 28 days from the nanofibrous membranes coating on the surface of the stents in vitro and in vivo. The vildagliptin-eluting PLGA membranes greatly accelerated the recovery of diabetic endothelia and reduced SMC hyperplasia. The type I collagen content of the diabetic vascular intimal area that was treated by vildagliptin-eluting stents was lower than that of the non-vildagliptin-eluting group.Conclusion: The experimental results revealed that stenting with vildagliptin-eluting PLGA membranes could potentially promote healing for diabetic arterial diseases.Keywords: re-endothelialization, neointimal hyperplasia, vildagliptin, biodegradable drug-eluting nanofibers
format	article
author	Lee CH Hsieh MJ Chang SH Hung KC Wang CJ Hsu MY Juang JH Hsieh IC Wen MS Liu SJ
author_facet	Lee CH Hsieh MJ Chang SH Hung KC Wang CJ Hsu MY Juang JH Hsieh IC Wen MS Liu SJ
author_sort	Lee CH
title	Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo
title_short	Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo
title_full	Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo
title_fullStr	Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo
title_full_unstemmed	Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo
title_sort	nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/2275f98c1f4f435997c75585a3008f42
work_keys_str_mv	AT leech nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT hsiehmj nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT changsh nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT hungkc nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT wangcj nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT hsumy nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT juangjh nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT hsiehic nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT wenms nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo AT liusj nanofibrousvildagliptinelutingstentsenhancereendothelializationandreduceneointimalformationindiabetesinvitroandinvivo
_version_	1718400578201059328

Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo

Ejemplares similares